Serum Follicle-Stimulating Hormone and 5-Year Change in Adiposity in Healthy Postmenopausal Women

Mattick, Lindsey J; Bea, Jennifer W.; Singh, Lawanya; Hovey, Kathleen M.; Banack, Hailey R.; Wactawski‐Wende, Jean; Manson, Jo Ann E.; Funk, Janet L.; Ochs‐Balcom, Heather M.

doi:10.1210/clinem/dgac238

Cited by 9 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 , 11 In this regard, FSH has been implicated in contributing to the adiposity and cardiometabolic changes in the postmenopausal period. 13 Prospective studies, such as the Study of Women Across the Nation (SWAN) study, have demonstrated different patterns of change in these hormones surrounding the menopause transition, based in part on body size and race/ethnicity. 14 , 15 For example, estradiol first slowly increases leading up to the perimenopausal stage then sharply decreases within one to two years of menopause in approximately 45% of women, while it slowly declines or remains relatively steady in other women.…”

Section: The Physiology Of Menopausementioning

confidence: 99%

A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

Madsen¹,

Sobel²,

Negash³

et al. 2023

IJWH

Self Cite

View full text Add to dashboard Cite

Understanding the role of both menopausal hormone therapy (MHT) along with non-hormonal options for the treatment of vasomotor symptoms, sleep disruption, and genitourinary symptoms after menopause is critical to the health of women during middle and later life. Recent updates to the evidence for the treatment of menopausal symptoms pertaining to both hormonal and non-hormonal therapies as well as updated guidance from specialty societies can help guide clinicians in their treatment of women going through natural menopause or with estrogen deficiencies due to primary ovarian insufficiency or induced menopause from surgery or medications. The objective of this narrative review is to provide clinicians with an overview of MHT for the use of menopausal symptoms in women, incorporating updated primary evidence for risk versus benefit profiles, recent specialty society recommendations, and alternative, non-hormonal options. In this review, we summarize literature on the use of MHT for menopause-related symptomatology including options for formulations and dosages of MHT, non-hormonal treatment options, and the risk–benefit profile of MHT including long-term health consequences (eg, cardiovascular disease, cognitive decline, venous thromboembolism, and fracture risk). Finally, we highlight areas in which future research is needed to advance care of women after menopause. In summary, both hormonal (MHT) and non-hormonal options exist to treat symptoms of menopause. There is strong evidence for safety and effectiveness of MHT for the treatment of vasomotor symptoms among women who are less than 60 years of age, less than 10 years since menopause, and without significant cardiometabolic comorbidities. For others, treatment with hormonal versus non-hormonal therapies can be considered based on individual risk profiles, as well as other factors such as drug formulation, therapeutic goals, and symptom severity.

show abstract

Section: The Physiology Of Menopausementioning

confidence: 99%

A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

Madsen¹,

Sobel²,

Negash³

et al. 2023

IJWH

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a longitudinal study (667 menopausal women), FSH increased by a maximum of 33.9 mIU/ml in menopausal women who discontinued hormone therapy, and elevated FSH was associated with increases in body fat, body fat mass, and subcutaneous fat percentage ( Mattick et al, 2022 ). However, Wu recently found no correlation between FSH and changes in bone mass and body composition ( Wu et al, 2021 ).…”

Section: Epidemiological Characteristics Of Fsh Level and Body Compos...mentioning

confidence: 99%

Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause

et al. 2022

View full text Add to dashboard Cite

Lipid metabolism disorder is a common pathological manifestation of menopausal women, and is also an important risk factor for many diseases at this stage of life. Epidemiological studies have shown that high levels of follicle-stimulating hormone (FSH) in menopausal women are closely associated with changes in body composition, central obesity, and cognitive decline. Exogenous FSH causes growth and proliferation of adipose, whereas blockage of the FSH signaling pathway leads to decline in adipose. Mechanistically, FSH, FSH receptor (FSHR), G protein coupling, gene mutation and other pathways are involved in adipogenesis and cognitive impairment. Here, we review the critical role and potential interactions of FSH in adipogenesis and cognitive impairment in menopausal women. Further understanding of the exact mechanisms of FSH aggravating obesity and cognitive impairment may provide a new perspective for promoting healthy aging in menopausal women.

show abstract

“…Large epidemiologic data have shown significant reductions in bone mineral density (BMD) and high resorption rates 2–3 years prior to menopause, when FSH serum levels are increasing, which is also associated with increased body weight and visceral adiposity ( Thurston et al, 2009 ; Senapati et al, 2014 ). A longitudinal study involving post-menopausal women has shown that increases in circulating FSH levels were associated with greater increases in the percentage of total body fat, total body fat mass, and subcutaneous adipose tissue ( Mattick et al, 2022 ). Moreover, clinical studies have found that FSH is also involved in the modulation of lean mass.…”

Section: Introductionmentioning

confidence: 99%

Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study

Bergamini,

Dalla Volta,

Palumbo

et al. 2024

eLife

View full text Add to dashboard Cite

Background:Among its extragonadal effects, follicle-stimulating hormone (FSH) has an impact on body composition and bone metabolism. Since androgen deprivation therapy (ADT) has a profound impact on circulating FSH concentrations, this hormone could potentially be implicated in the changes of fat body mass (FBM), lean body mass (LBM), and bone fragility induced by ADT. The objective of this study is to correlate FSH serum levels with body composition parameters, bone mineral density (BMD), and bone turnover markers at baseline conditions and after 12 months of ADT.Methods:Twenty-nine consecutive non-metastatic prostate cancer (PC) patients were enrolled from 2017 to 2019 in a phase IV study. All patients underwent administration of the luteinizing hormone-releasing hormone antagonist degarelix. FBM, LBM, and BMD were evaluated by dual-energy x-ray absorptiometry at baseline and after 12 months of ADT. FSH, alkaline phosphatase, and C-terminal telopeptide of type I collagen were assessed at baseline and after 6 and 12 months. For outcome measurements and statistical analysis, t-test or sign test and Pearson or Spearman tests for continuous variables were used when indicated.Results:At baseline conditions, a weak, non-significant, direct relationship was found between FSH serum levels and FBM at arms (r = 0.36) and legs (r = 0.33). Conversely, a stronger correlation was observed between FSH and total FBM (r = 0.52, p = 0.006), fat mass at arms (r = 0.54, p = 0.004), and fat mass at trunk (r = 0.45, p = 0.018) assessed after 12 months. On the other hand, an inverse relationship between serum FSH and appendicular lean mass index/FBM ratio was observed (r = −0.64, p = 0.001). This is an ancillary study of a prospective trial and this is the main limitation.Conclusions:FSH serum levels after ADT could have an impact on body composition, in particular on FBM. Therefore, FSH could be a promising marker to monitor the risk of sarcopenic obesity and to guide the clinicians in the tailored evaluation of body composition in PC patients undergoing ADT.Funding:This research was partially funded by Ferring Pharmaceuticals. The funder had no role in design and conduct of the study, collection, management, analysis, and interpretation of the data and in preparation, review, or approval of the manuscript.Clinical trial number:clinicalTrials.gov NCT03202381, EudraCT Number 2016-004210-10.

show abstract

Serum Follicle-Stimulating Hormone and 5-Year Change in Adiposity in Healthy Postmenopausal Women

Cited by 9 publications

References 24 publications

A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause

Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study

Contact Info

Product

Resources

About